ODOla Deghedy

Ola Deghedy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ola Deghedy has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The National Burden of Influenza‐Associated Respiratory Illness Across Levels of Severity in Egypt, 2016–2019

    by Manal Fahim, Ola Deghedy, Walaa Alim, Reham Kamel, Hossam Hassan, Amira Mohsen, Rania Attia, Hala Abou El Naja, Salma Afifi, Stefano Tempia, et al.

    Introduction: Influenza burden (IB) estimates are crucial for monitoring disease trends, allocating limited resources, and promoting influenza vaccination. However, IB in Egypt is poorly understood. This study estimates the mean‐seasonal IB in Egypt, across levels of severity by age and regions using sentinel surveillance data between 2016 and 2019.Methods: Influenza surveillance was implemented among patients hospitalized with severe acute respiratory infection (SARI) at eight sentinel hospitals across Egypt. We estimated the influenza‐associated SARI hospitalization in two governorates and then extrapolated nationally using the World Health Organization (WHO)–recommended methods. Thereafter, we estimated IB‐associated mild/moderate illness and deaths using IB pyramid tool developed by WHO and the John Hopkins Center for Health Security. Rates were reported per 100,000 population.Results: The estimated mean seasonal number of influenza‐associated mild/moderate illness, hospitalized noncritically and critically ill patients, and deaths was 16,425,938 (95% CI: 1,150,888–40,409,614), 30,335 (95% CI: 9971–670,288), 9110 (95% CI: 580–16,321), and 2660 (95% CI: 154–9908), respectively. The highest rate of influenza‐associated mild/moderate illness was among aged 5–14 year (22,932; 95% CI: 825–25,546.3), whereas the highest rates of severe influenza were among aged > 65 years (hospitalizations: 159.4, 95% CI: 121.7–205.0; deaths: 56.0, 95% CI: 0.6–111.0). Children aged < 5 years also experience high rates of influenza‐associated hospitalization (52.0, 95% CI: 43.0–62.0).Conclusions: The WHO method estimated a high burden of severe influenza among aged ≥ 65 and aged < 5 years in Egypt. To reduce severe IB, increased influenza vaccine uptake together with enhanced immunization strategies implementations among the elderly and children are warranted.


  • Open Access

    Comparative analysis of COVID-19 and influenza prevalence among Egyptian pilgrims returning from Hajj and Umrah in 2022: epidemiology, clinical characteristics, and genomic sequencing

    by Amr Kandeel, Manal Fahim, Ola Deghedy, Hala BahaaEldin, Wael H. Roshdy, Mohamed Kamal Khalifa, Ahmed Kandeil, Rabeh El Shesheny, Amel Naguib, Mohamad AbdelFatah, et al.

    Purpose: To describe the changes that occurred in the SARS-CoV-2 and influenza Prevalence, epidemiology, clinical picture, and prevalent genotypes among the Egyptian pilgrims returning from Hajj and Umrah 2022 seasons. Methods: Pilgrims were contacted at the airport and invited to participate in the survey. Pilgrims who consented were interviewed using a standardized line list that included participant demographics, respiratory symptoms if any, previous COVID-19 infection, influenza vaccination whereas COVID-19 vaccination information were collected from vaccination cards. Participants were asked to provide throat and nasopharyngeal swabs for SARS-CoV-2 and influenza testing using RT-PCR and a subset of isolates were sequenced. Descriptive data analysis was performed to describe the epidemiology and clinical symptoms of SARS-CoV-2 and influenza. Prevalence rates of SARS-CoV-2 and influenza during Hajj were calculated and compared to Umrah surveys using chi2 and t-test with a significance level < 0.05. Results: Overall, 3,862 Egyptian pilgrims enrolled, their mean age was 50.5 ± 47 years, half of them were > 50 years of age and 58.2% were males. Of them, 384 (9.9%) tested positive for SARS-CoV-2 and 51 (1.3%) for influenza viruses. Prevalence of SARS-CoV-2 infections (vaccine breakthrough) increased significantly between the Umrah and Hajj surveys (6.7% vs. 9.9%, p < 0.001), and variants of the virus varied considerably. Whereas no significant difference was found in influenza prevalence, vaccine coverage and vaccine breakthrough infection rates (11.7 vs. 9.2%, 26.9 vs. 26.8%, and 1.4 vs. 1.1% respectively). Conclusions: SARS-CoV-2 prevalence among Egyptian pilgrims returning from Hajj in July increased with reduced vaccine effectiveness compared to Umrah in March 2022 suggesting a possible wave of SARS-CoV-2 in the upcoming winter.


  • Open Access

    Multicenter study to describe viral etiologies, clinical profiles, and outcomes of hospitalized children with severe acute respiratory infections, Egypt 2022

    by Amr Kandeel, Manal Fahim, Ola Deghedy, Wael H. Roshdy, Mohamed K. Khalifa, Rabeh El Shesheny, Ahmed Kandeil, Saly Wagdy, Amel Naguib, Salma Afifi, et al.

    In late 2022, severe acute respiratory infections (SARI) surveillance reported an abrupt increase in non-COVID-19 infections among children after three years of drastic reductions. Signals of increased absenteeism due to respiratory symptoms among primary and preparatory school children were detected by Event-Based Surveillance. We conducted a hospital-based survey of children who were admitted with SARI to identify the causative pathogen(s) and estimate the burden of infection. A survey was conducted among children < 16 years in 21 referral hospitals in the three governorates with the highest SARI rates. Patients’ demographics, clinical symptoms, and severity were collected from medical records using a line list. Patients were swabbed and tested for a panel of 33 respiratory pathogens by RT-PCR at the Central Laboratory in Cairo. Descriptive data analysis was performed for demographic data. Patients’ characteristics were compared by causative agents’ clinical picture and severity using Chi2 with a p < 0.05 significance. Overall, 317 patients were enrolled, 58.3% were ≤ 1 year of age, 61.5% were males. Of 229 (72.7%) of positively tested patients, viruses caused 92.1% including RSV 63.8%, Rhinovirus 10.0%, Influenza 9.2%, Adenovirus 5.2%, and 1.3% co-infected with two viruses. Bacteria caused 3.5% of cases and 4.4% had mixed viral-bacterial infections. Rhinovirus was the most common cause of death among children with SARI, followed by RSV (8.7% and 1.4%), whereas influenza and Adenovirus did not result in any deaths. Patients with viral-bacterial infections are more likely to be admitted to ICU and die at the hospital than bacterial or viral infections (60% and 20% vs. 31.8% and 1.9% vs. 12.5% and 12.5%, p < 0.001). Viruses particularly RSV are the leading cause of SARI causing significant health problem among children < 16 years in Egypt. Bacterial on top of viral infection can worsen disease courses and outcomes. Studies are required to estimate the SARI burden accurately among Egyptian children and a comprehensive approach tailored to Egypt is necessary to reduce its burden.


  • Open Access

    Clinical features and severe outcome predictors of COVID-19 vaccine breakthrough infection among hospitalized patients: results from Egypt severe acute respiratory infections sentinel surveillance, 2021–2022

    by Amr Kandeel, Manal Fahim, Ola Deghedy, Walaa Alim, Mohammad Abdel Fattah, Salma Afifi, Amira Mohsen, Khaled Abdelghaffar

    Background: COVID-19 vaccines are effective against infections and outcomes; however, breakthrough infections (VBT) are increasingly reported, possibly due to waning of vaccine-induced immunity or emerging variants. Most studies have focused on determining VBT rate based on antibody levels. This study aims at describing clinical features, risks, time trends, and outcomes of COVID-19 VBT among hospitalized patients in Egypt. Methods: Data of SARS-CoV-2 confirmed patients hospitalized in 16 hospitals was obtained from the severe acute respiratory infections surveillance database, September 2021-April 2022. Data includes patients’ demographics, clinical picture, and outcomes. Descriptive analysis was performed and patients with VBT were compared to not fully vaccinated (UPV). Bivariate and multivariate analyses were performed using Epi Info7 with a significance level < 0.05 to identify VBT risk factors. Results: Overall, 1,297 patients enrolled, their mean age 56.7 ± 17.0 years, 41.5% were males, 64.7% received inactivated, 25.% viral vector, and 7.7% mRNA vaccine. VBT was identified in 156(12.0%) patients with an increasing trend over time. VBT significantly was higher in (16–35 years) age, males, in those who received inactivated vaccine compared to corresponding groups of UPV (14.1 vs. 9.0%, p < 0.05 and 57.1 vs. 39.4%, p < 0.001 and 64.7 vs. 45.1, p < 0.01 respectively). Whereas receiving mRNA vaccine was significantly protective against VBT (7.7 vs. 21.6%, p < 001). VBT patients tend to have shorter hospital stays and lower case fatality (mean hospital days = 6.6 ± 5.5 vs. 7.9 ± 5.9, p < 0.01 and CFR = 28.2 vs. 33.1, p < 0.01 respectively). MVA identified younger ages, male gender, and inactivated vaccines as risks for VBT. Conclusion: The study indicated that COVID-19 vaccines significantly reduce hospital days and fatality. VBT trend is on the rise and males, young ages, and inactivated vaccine receivers are at higher risk. Caution regarding relaxation of personal preventive measures in areas with higher or increasing incidences of COVID-19, particularly for the at-risk group even if they are vaccinated. The vaccination strategy should be revised to reduce VBT rate and increase vaccine effectiveness.


  • Open Access

    Adapting an integrated acute respiratory infections sentinel surveillance to the COVID-19 pandemic requirements, Egypt, 2020–2022

    by Manal Fahim, Hanaa Abu ElSood, Basma AbdElGawad, Ola Deghedy, Amel Naguib, Wael H. Roshdy, Shymaa Showky, Reham Kamel, Nancy Elguindy, Mohammad Abdel Fattah, et al.


  • Open Access

    Epidemiology, Disease Severity and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Viruses Coinfection Seen at Egypt Integrated Acute Respiratory Infections Surveillance, 2020–2022

    by Manal Fahim, Wael H. Roshdy, Ola Deghedy, Reham Kamel, Amel Naguib, Shymaa Showky, Nancy Elguindy, Mohammad Abdel Fattah, Salma Afifi, Amira Mohsen, et al.

    Background. Cocirculation of influenza (Flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2/Flu) represent a public health concern as it may worsen the severity and increase fatality from coronavirus disease 2019. An increase in the number of patients with coinfection was recently reported. We studied epidemiology, severity, and outcome of patients with SARS-CoV-2/Flu coinfection seen at Egypts integrated acute respiratory infections surveillance to better describe disease impact and guide effective preventive measures. Methods. The first two outpatients were seen daily, and every fifth patient admitted to 19 sentinel hospitals with respiratory symptoms was enrolled. Patients were interviewed using a standardized questionnaire and provided nasopharyngeal swabs to be tested for SARS-CoV-2 and influenza by real-time polymerase chain reaction at the central laboratory. Data from all patients with coinfection were obtained, and descriptive data analysis was performed for patients demographics, clinical course, and outcome. Results. The total number of patients enrolled between January 2020 and April 2022 was 18,160 and 6,453 (35.5) tested positive for viruses, including 52 (0.8) coinfection. Of them, 36 (69.2) were coinfected with Flu A/H3, 9 (17.3) Flu-B, and 7 (13.5) Flu A/H1. Patients mean age was 33.2±21, 55.8 were males, and 20 (38.5) were hospitalized, with mean hospital days 6.7±6. At the hospital, 14 (70.0) developed pneumonia, 6 (30.0) ICU admitted, and 4 (20.0) died. The hospitalization rate among patients coinfected with Flu-B and Flu A/H3 was 55.6 and 41.7, with mean hospital days (8.0±6 and 6.4±6), pneumonia infection (40.0 and 80.0), ICU admission (40.0 and 26.7), and death (20.0 for both), while no patients hospitalized with A/H1. Conclusions. The recent increase in the number of SARS-CoV-2/Flu coinfections was identified in Egypt. The disease could have a severe course and high fatality, especially in those coinfected with Flu-B and Flu A/H3. Monitoring disease severity and impact is required to guide preventive strategy.


  • Open Access

    Incidence, risk factors, and whole-genome sequence of SARs-CoV-2 and influenza virus among the Egyptian pilgrims returning from Umrah mass gathering in Saudi Arabia, April-May 2022

    by Amr Kandeel, Manal Fahim, Ola Deghedy, Walaa Alim, Wael H. Roshdy, Mohamed K. Khalifa, Rabeh El Shesheny, Ahmed Kandeil, Amel Naguib, Nancy Elguindy, et al.